Amgen

Regeneron Secures $400M Jury Victory as Amgen Faces Antitrust Liability

by

REGIONAL, USA — A federal jury delivered a significant verdict in favor of Regeneron Pharmaceuticals, awarding the company over $400 million in damages in a high-stakes antitrust case against Amgen. The jury found Amgen liable for anticompetitive conduct related to its marketing strategies for a key medication used in treating certain eye diseases. The lawsuit, which made its way to the courtroom after years of legal maneuvering, centered on Amgen’s alleged efforts to stifle competition in the market for treatments, potentially affecting thousands of patients. The jury’s decision signals a clear stance against practices that … Read more

Amgen Faces $400M+ Liability to Regeneron Following Antitrust Ruling on Cholesterol Drug

by

Amgen, a prominent biotechnology company based in Thousand Oaks, California, faces potential financial ramifications exceeding $400 million following a significant antitrust lawsuit concerning its cholesterol-lowering medication. The outcome of this legal battle could have substantial consequences for both Amgen and its competitor Regeneron Pharmaceuticals. The lawsuit, which centered on allegations of anti-competitive practices, has drawn attention to the ongoing efforts within the pharmaceutical industry to navigate regulatory frameworks while maintaining competitive pricing for consumers. The jury’s decision in favor of Regeneron underscores the legal challenges that can arise when companies seek to protect their market … Read more

Regeneron Secures $400 Million Victory in Landmark Antitrust Ruling Against Amgen

by

Bridgewater, New Jersey — A jury has awarded Regeneron Pharmaceuticals Inc. $400 million in a significant antitrust case against rival Amgen Inc. This landmark decision underscores the ongoing legal battles over market competition and patent rights in the biotechnology sector. The case revolved around claims that Amgen engaged in anti-competitive practices that harmed Regeneron’s business interests. The jury’s verdict reinforces Regeneron’s position, alleging that Amgen’s actions restricted the market and competitive landscape for vital medications. Both companies are significant players in the pharmaceutical industry, with a focus on cutting-edge treatments. Regeneron, known for its work … Read more

Switzerland’s Sandoz Takes Legal Action Against Amgen, Alleging Antitrust Violations in the US

by

Basel, Switzerland – Sandoz, a division of Swiss pharmaceutical giant Novartis AG, has launched an antitrust lawsuit against Amgen Inc. in the United States, accusing the American biotechnology firm of engaging in anti-competitive practices. The legal action, filed in the U.S. District Court for the Eastern District of Pennsylvania, alleges that Amgen has been blocking biosimilar competition to its white blood cell-boosting drugs, Neulasta and Neupogen, thus monopolizing the market. Sandoz argues that Amgen has set up a series of obstacles – ranging from questionable patents to exclusionary contracts with healthcare providers – effectively stifling … Read more